Literature DB >> 11096558

Small Bowel Dysmotility.

.   

Abstract

The most important initial step in treating patients with intestinal dysmotility is to exclude reversible causes, in particular mechanical obstruction. The presence or absence of bacterial overgrowth should be determined by small bowel aspirate or breath test, although an empiric trial with antibiotics is an appropriate alternative. Physicians should use agents effective against gram-negative organisms, such as broad-spectrum penicillins or tetracycline, particularly those that provide coverage of anaerobes, such as metronidazole. Nutritional support, by enteral or parenteral means, is currently the most important aspect of management of patients with severe intestinal dysmotility. A low-fat diet, supplemented by liquid formulas, can be tried first. The presence of gastroparesis should be determined; if severe, jejunal feeding should be attempted. Because of the costs and risks associated with total parenteral nutrition (TPN), every attempt should be made to use the native intestine for feeding. A trial of several days of naso-jejunal feeding can help select those patients who can obtain sufficient nutrition by enteral routes and is recommended prior to committing a patient to TPN therapy. Even while on TPN, some oral intake should be encouraged. Prokinetic agents currently in use are less effective in the small bowel than they are in the stomach. They should always be tried initially, though, particularly because improvement of concomitant gastric dysmotility can alleviate symptoms. Although certain manometric patterns can select those patients who respond better to therapy, manometry should not be used to direct therapy in individual patients. For the moment, cisapride is the drug of choice. Erythromycin, particularly when given intravenously and in small, sub-antibiotic doses, can also be tried. The role of octreotide is not clear, but when given at small doses, and when combined with erythromycin, it may be useful in selected patients. Ablative surgery may be useful in a few, highly selected patients. One of the most beneficial surgical procedures is a venting jejunostomy. The use of this simple intervention can substantially reduce the number of hospital admissions and emergency room visits in selected patients with intermittent obstructive symptoms.

Entities:  

Year:  1998        PMID: 11096558     DOI: 10.1007/s11938-998-0002-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  30 in total

1.  Total parenteral nutrition promotes bacterial translocation from the gut.

Authors:  J C Alverdy; E Aoys; G S Moss
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

2.  Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States.

Authors:  L Howard; M Ament; C R Fleming; M Shike; E Steiger
Journal:  Gastroenterology       Date:  1995-08       Impact factor: 22.682

3.  Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis.

Authors:  J Tack; J Janssens; G Vantrappen; T Peeters; V Annese; I Depoortere; E Muls; R Bouillon
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

4.  Current results of intestinal transplantation. The International Intestinal Transplant Registry.

Authors:  D Grant
Journal:  Lancet       Date:  1996-06-29       Impact factor: 79.321

5.  Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction.

Authors:  G N Verne; E Y Eaker; E Hardy; C A Sninsky
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

6.  Chronic intestinal pseudoobstruction in a patient with heart-lung transplant. Therapeutic effect of leuprolide acetate.

Authors:  J R Mathias; G S Baskin; V G Reeves-Darby; M H Clench; L L Smith; J H Calhoon
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

7.  Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination.

Authors:  V Annese; J Janssens; G Vantrappen; J Tack; T L Peeters; P Willemse; E Van Cutsem
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

8.  Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders.

Authors:  K Haruma; J A Wiste; M Camilleri
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

9.  The surgeon's role in the treatment of chronic intestinal pseudoobstruction.

Authors:  M M Murr; M G Sarr; M Camilleri
Journal:  Am J Gastroenterol       Date:  1995-12       Impact factor: 10.864

10.  Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration.

Authors:  W Londong; M Angerer; K Kutz; R Landgraf; V Londong
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

View more
  2 in total

Review 1.  Small bowel motility: ready for prime time?

Authors:  E E Soffer
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 2.  Nutrition support in a surgical patient.

Authors:  B R Thapa; Sujit Jagirdhar
Journal:  Indian J Pediatr       Date:  2002-05       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.